Literature DB >> 10768975

Human immune responses to Schistosoma mansoni vaccine candidate antigens.

A Ribeiro de Jesus1, I Araújo, O Bacellar, A Magalhães, E Pearce, D Harn, M Strand, E M Carvalho.   

Abstract

To determine the naturally occurring immunological responses to the Schistosoma mansoni antigens paramyosin, IrV-5, Sm-23 (MAP-3), and triose phosphate isomerase (MAP-4), a total of 119 subjects from an area of endemicity for schistosomiasis, including "resistant" subjects (n = 17) were evaluated. Specific immunoglobulin G1 (IgG1), IgG2, IgG3, IgG4, and IgA levels for each of the antigens and the cytokine profile in culture supernatants from antigen-stimulated peripheral blood mononuclear cells (PBMC) were determined. Although all the subjects had a high degree of contaminated water exposure, their infection levels were variable (0 to 1,128 eggs/g of stool). There were direct correlations between infection levels and levels of SWAP- and paramyosin-specific IgG1 and IgG4 (P < 0.05). However, an inverse correlation between infection levels and specific IgG2 to IrV-5 (P < 0.01) was observed. The evaluation of the cytokine profile (interleukin 5 [IL-5], IL-10, gamma interferon [IFN-gamma], and tumor necrosis factor alpha) in response to these antigens showed inverse correlations between the degree of infection and IFN-gamma levels in PBMC supernatants stimulated with paramyosin (P < 0.05) and IrV-5 (P < 0.01). Additionally, inverse correlations between the degree of infection and IL-5 levels in MAP-3- and MAP-4-stimulated PBMC supernatants (P < 0.01) were found. Logistic regression analysis was performed to adjust the results of cytokine profile by age. IL-5 production in MAP-3-stimulated PBMC supernatants was associated with lower infection levels (odds ratio = 11.2 [95% confidence interval, 2.7 to 45.8]).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768975      PMCID: PMC97490          DOI: 10.1128/IAI.68.5.2797-2803.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  70 in total

1.  Characterization and cloning of Schistosoma mansoni immunogens recognized by protective antibodies.

Authors:  M Strand; J P Dalton; T D Tom
Journal:  Acta Trop Suppl       Date:  1987-06

2.  Coprological diagnosis of schistosomiasis. I. Evaluation of quantitative techniques.

Authors:  N Katz; G Chaia
Journal:  Rev Inst Med Trop Sao Paulo       Date:  1968 Sep-Oct       Impact factor: 1.846

Review 3.  Prospects for immunological control of schistosomiasis.

Authors:  D W Dunne; P Hagan; F G Abath
Journal:  Lancet       Date:  1995-06-10       Impact factor: 79.321

4.  Schistosoma mansoni: detection by monoclonal antibody of a 22,000-dalton surface membrane antigen which may be blocked by host molecules on lung stage parasites.

Authors:  D A Harn; M Mitsuyama; E D Huguenel; J R David
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

5.  Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy.

Authors:  C E Demeure; P Rihet; L Abel; M Ouattara; A Bourgois; A J Dessein
Journal:  J Infect Dis       Date:  1993-10       Impact factor: 5.226

6.  Induction of protective immunity against Schistosoma mansoni by vaccination with schistosome paramyosin (Sm97), a nonsurface parasite antigen.

Authors:  E J Pearce; S L James; S Hieny; D E Lanar; A Sher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

7.  In vivo T cell depletion regulates resistance and morbidity in murine schistosomiasis.

Authors:  S M Phillips; G P Linette; B L Doughty; J E Byram; F Von Lichtenberg
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

8.  Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium.

Authors:  P Hagan; U J Blumenthal; D Dunn; A J Simpson; H A Wilkins
Journal:  Nature       Date:  1991-01-17       Impact factor: 49.962

Review 9.  Schistosome vaccines: current progress and future prospects.

Authors:  A Sher; S L James; R Correa-Oliveira; S Hieny; E Pearce
Journal:  Parasitology       Date:  1989       Impact factor: 3.234

10.  Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.

Authors:  A E Butterworth; M Capron; J S Cordingley; P R Dalton; D W Dunne; H C Kariuki; G Kimani; D Koech; M Mugambi; J H Ouma
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

View more
  31 in total

1.  Factors associated with resistance to Schistosoma mansoni infection in an endemic area of Bahia, Brazil.

Authors:  Ricardo R Oliveira; Joanemile P Figueiredo; Luciana S Cardoso; Rafael L Jabar; Robson P Souza; Martin T Wells; Edgar M Carvalho; Daniel W Fitzgerald; Kathleen C Barnes; Maria Ilma Araújo; Marshall J Glesby
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum.

Authors:  Tjalling Leenstra; Luz P Acosta; Hai-Wei Wu; Gretchen C Langdon; Julie S Solomon; Daria L Manalo; Li Su; Mario Jiz; Blanca Jarilla; Archie O Pablo; Stephen T McGarvey; Remigio M Olveda; Jennifer F Friedman; Jonathan D Kurtis
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Still hope for schistosomiasis vaccine.

Authors:  Alessandra Ricciardi; Momar Ndao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Identification of paramyosin T cell epitopes associated with human resistance to Schistosoma mansoni reinfection.

Authors:  C T Fonseca; E Cunha-Neto; A C Goldberg; J Kalil; A R de Jesus; E M Carvalho; R Correa-Oliveira; J Hammer; J Sidney; A Sette; S C Oliveira
Journal:  Clin Exp Immunol       Date:  2005-12       Impact factor: 4.330

Review 5.  Helminth infections and host immune regulation.

Authors:  Henry J McSorley; Rick M Maizels
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

6.  Molecular cloning and characterization of a paramyosin from Clonorchis sinensis.

Authors:  Tae-Joon Park; Jung-Mi Kang; Byoung-Kuk Na; Woon-Mok Sohn
Journal:  Korean J Parasitol       Date:  2009-12-01       Impact factor: 1.341

Review 7.  Current status of vaccines for schistosomiasis.

Authors:  Donald P McManus; Alex Loukas
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

8.  Immunoglobulin E (IgE) responses to paramyosin predict resistance to reinfection with Schistosoma japonicum and are attenuated by IgG4.

Authors:  Mario Jiz; Jennifer F Friedman; Tjalling Leenstra; Blanca Jarilla; Archie Pablo; Gretchen Langdon; Sunthorn Pond-Tor; Hai-Wei Wu; Daria Manalo; Remigio Olveda; Luz Acosta; Jonathan D Kurtis
Journal:  Infect Immun       Date:  2009-03-09       Impact factor: 3.441

9.  HTLV-1 modifies the clinical and immunological response to schistosomiasis.

Authors:  A F Porto; S B Santos; L Alcantara; J B Guerreiro; J Passos; T Gonzalez; F Neva; D Gonzalez; J L Ho; E M Carvalho
Journal:  Clin Exp Immunol       Date:  2004-08       Impact factor: 4.330

10.  Expression of a 28-kilodalton glutathione S-transferase antigen of Schistosoma mansoni on the surface of filamentous phages and evaluation of its vaccine potential.

Authors:  Kakuturu V N Rao; Yi-Xun He; Ramaswamy Kalyanasundaram
Journal:  Clin Diagn Lab Immunol       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.